2026 Critical Care Congress Skip to main content
2026 Critical Care Congress Main banner
Final Program


Advance Program
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Session Icons
Thought Leader Session
Thought Leader Session
Guidelines Session
Guidelines Session
Aging Adult Track
Aging Adult Track
Additional Registration Fee
Additional Registration Fee

Research Snapshot Theater: Sepsis, Adult III

Predicting Survival Benefit of Early Vasopressor Use in Septic Shock: A Multicenter Cohort Study

Sunday, March 22, 2026
12:15 PM - 1:15 PM Central Time
Location: Connections Central - RST 14
  • EC

    Eunjeong Choi, MD (she/her/hers)

    Pusan National University Yangsan Hospital, Republic of Korea

    Disclosure(s): No relevant financial relationship(s) to disclose.

  • JJ

    Jinho Jang, MD

    Assistant Professor
    Division of Allergy, Pulmonary and Critical Care Medicine, Department of Internal Medicine, Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital

    Disclosure information not submitted.

  • WC

    WooHyun Cho, MD, PhD

    Professor
    Division of Allergy, Pulmonary and Critical Care Medicine, Department of Internal Medicine, Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital

    Disclosure information not submitted.

  • HY

    Hyeju Yeo, MD, PhD

    Assistant Professor
    Division of Allergy, Pulmonary and Critical Care Medicine, Department of Internal Medicine, Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital

    Disclosure information not submitted.

Introduction: Early administration of vasopressors in septic shock may improve survival, but not all patients derive equal benefit. We aimed to develop a prognostic model to identify patients who are more likely to survive with early vasopressor therapy.


Methods: We analyzed data from a prospective multicenter cohort of adult patients with sepsis admitted to Korean hospitals between September 2019 and May 2023. Of 17,828 sepsis patients, 3,064 had septic shock. Early vasopressor use was defined as initiation within 1 hour after adequate fluid resuscitation. We excluded patients who did not receive fluid loading (n=275), did not receive vasopressors (n=20), received vasopressors prior to fluid loading (n=417), or received vasopressors more than 1 hour after fluid resuscitation (n=353). The final cohort included 1,999 patients who received early vasopressor therapy following fluid loading.


Results: Among these patients, 1,259 survived and 740 died within 28 days. Using forward selection, 14 variables were identified as significantly associated with 28-day survival: initial lactate level, clinical frailty score, chronic neurologic disease, blood urea nitrogen, SOFA-pF score, Charlson comorbidity index, body mass index, hematocrit, urinary tract infection, age, brain natriuretic peptide, aspartate aminotransferase, C-reactive protein, and SOFA-cardiovascular score. A survival prediction model was developed and internally validated using a 7:3 split into training and validation datasets. The model demonstrated good discriminative performance, with an area under the receiver operating characteristic curve (AUC) of 0.781 in the training set and 0.798 in the validation set.


Conclusions: We developed a clinically applicable prediction model to identify septic shock patients who are most likely to benefit from early vasopressor therapy. This tool may support individualized decision-making during the early phase of sepsis management.